CGC
Canopy GrowthANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
Current thesis
The constructive case is narrow: Canopy has completed the MTL transaction, still reports a meaningful cash balance, and now has time to show that integration can improve the quality of the Canadian medical business without an immediate financing event [#8-K-2026-03-16] [#10-Q-2026-02-06].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Canadian pricing and category competition offset any medical-market gains
Momentum
92
Value
41
Sentiment
59
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.20 · Bull $1.80 · Bear $0.60
Data freshness
Prices
As of 2026-06-11
Fundamentals
As of 2026-06-11 • Vendor: Data Vendor v1
Scores
As of 2026-06-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-11
Investment thesis
As of 2026-06-11
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $1.81
Why
Momentum92 · Δ7d -
Value41 · Δ7d -0.1
Sentiment59 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
92
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.1
Sentiment
59
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 92.2 / Value 41.0 / Sentiment 59.3
Fundamentals (TTM)As of 2026-06-11
Fundamentals (TTM)
As of 2026-06-11
Market Cap
$459.74M
Beta
0.57
Shares Out
342.2M
P/E (TTM) · Derived
-0.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-99.52
Rev YoY
+5.9%
EPS YoY
-3.0%
Gross Margin
+27.5%
Op Margin
-29.8%
Net Debt
$139.37M
Current Ratio
3.21
As of 2026-06-11 • Updated nightlySource: Internal modelMethodology